Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 388

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 388
---
 |           |   40 |   |     |            | 1,259 |   |     |        |  371 |   |     |       | 1,727 |   |
| Net book value           |     |              |     |   |     |              |    |   |     |           |      |   |     |            |       |   |     |        |      |   |     |       |       |   |
| At 31 December 2023      |     |              |  32 |   |     |              | 27 |   |     |           |   10 |   |     |            |   152 |   |     |        |  350 |   |     |       |   571 |   |
| At 31 December 2022      |     |              |  44 |   |     |              | 38 |   |     |           |   17 |   |     |            |   245 |   |     |        |  487 |   |     |       |   831 |   |
| At 31 December 2021      |     |              |  53 |   |     |              | 49 |   |     |           |   29 |   |     |            |   358 |   |     |        |  663 |   |     |       | 1,152 |   |

As
at 31 December right of use asset consisted of leasehold improvements of net book value £350k (2022: £485k; 2021: £619k)
and laboratory equipment of net book value £Nil (2022: £2k; 2021: £44k).

On
1 February 2023 laboratory equipment previously disclosed within right of use assets was transferred to laboratory equipment when the
final payment on the finance lease was made. On 1 January 2022 software previously disclosed within computer equipment was transferred
to intangible assets.

| F-48 |

| 10 | Leases |

| Schedule of market rental rates       |     |            |   |     |            |   |     |            |   |
| Lease Liabilities                     |     | 2023 £’000 |   |     | 2022 £’000 |   |     | 2021 £’000 |   |
| At 1 January                          |     |        624 |   |